Purpose: We evaluated the Optia® continuous mononuclear collection (CMNC) system for hematopoietic progenitor cell-apheresis (HPC-A) collection (Terumo BCT, Lakewood, CO) compared to the COBE® Spectra (Terumo BCT, Lakewood, CO), including both large volume leukapheresis (LVL) and non-LVL collections.
apheresis system (Terumo BCT, Lakewood, Colorado) is a newer system with several upgrades including an automated interface management system that automatically detects and maintains buffy coat interface for HPC collection. [4] [5] [6] Low volume tubing set and lower extracorporeal volumes are incorporated in this system to reduce platelet attrition. 7 Additional features such as an intuitive graphical user interface and software program were developed to streamline procedure management. In contrast to the COBE® Spectra apheresis system, in which white blood cells are continually collected from the buffy coat into the collection bag, the earlier Spectra Optia® apheresis system (Spectra Optia version 7.2) only supported a dual-step mononuclear cell (MNC) processing. During the first step, the platelet-rich buffy coat was directed to an intermediate collection chamber that preferentially retained white blood cells but returned the majority of the platelets to the donor. In the second step, the white blood cells were intermittently flushed into the collection bag once red blood cell overflow was detected by the optical sensors. Occasionally, chamber flushing did not occur automatically despite overflow, and needed to be triggered manually by the operator. 4 The Optia® continuous mononuclear collection (CMNC) apheresis system (Spectra Optia version 11.2), a newer version of the the Spectra Optia® apheresis system, eliminates the intermediate collection chamber and allows for the white blood cells to be continually collected from the buffy coat into the collection bag. It is believed this newer system is easier, less time-consuming and more manageable to operate.
To date, only a few studies have compared the performance characteristics of the two apheresis systems: Spectra Optia versus Cobe Spectra 8 and MNC versus CMNC Spectra Optia, 9 and no comparison studies have been performed within the United States utilizing large volume leukapheresis (LVL). LVL usually involves processing 3 to 6 3 Total Blood Volume (TBV) in comparison to 2-3 TBV in the non-LVL setting. Prior studies 10, 11 have shown higher HPC yields with LVL procedures, making LVL collections particularly helpful in achieving the collection goal in patients who mobilize poorly. The aim of this study was to validate the equivalence of performance of the new Optia® CMNC system with the existing COBE® Spectra, to provide a baseline for quality assurance. Manufacturer support of the COBE® Spectra apheresis system has been discontinued since January 2017, and hence it became essential to compare the two devices to ensure adequate performance and to verify improvements in the new system for optimal HPC collection.
| PA TI ENT S A ND M ETHO DS

| Patients
We performed a retrospective review of all autologous HPC-A collections performed using the new Optia® CMNC collection system (Terumo BCT, Lakewood, Colorado) since its implementation at our institution in August 2015 up to December 2016, and compared them with a similar number of concurrent collections utilizing the COBE® Spectra system (Terumo BCT, Lakewood, Colorado). Each patient who underwent collection utilizing the new Optia® CMNC system also underwent collection utilizing the COBE® Spectra system on a prior or a subsequent day. A total of 67 patients underwent 189 collections (93 on Optia® CMNC system and 96 on COBE® Spectra system). All collections represent single attempts at mobilization and collection. Patient characteristics are shown in Table 1 . This validation study was approved by the Institution Review Board of University of Arkansas for Medical Sciences, Little Rock (UAMS).
| Mobilization regimens
Mobilization was achieved using chemotherapy 1 G-CSF (n 5 108) (5-8 mg/kg BID), chemotherapy 1 G-CSF 1 plerixafor (n 5 67), G-CSF alone (n 5 10) or G-CSF 1 plerixafor (n 5 4) ("n" 5 number of collection days). The chemotherapy mobilization regimens are listed in Table 2 . G-CSF was initiated on Day 6 after completion of chemotherapy. Once the WBC count was 2 3 10 9 /L, daily CD34 values prior to collection (precounts) were obtained.
| Apheresis
The predicted collection of CD341 cells/kg was calculated based on our minimum predicted collection formula 12 
:
Minimum CD341 cells predicted to be collected per liter of blood processed5 (peripheral blood CD341 cells/L) 3 (adjusted collection efficiency of 30%)/body weight (kg).
Autologous HPC-A collection was initiated when the CD341 cell collection for 30 L of blood processed (LVL) was 1 3 10 6 cells/kg for first time collectors or 0.5 3 10 6 cells/kg in returning collectors who had previously failed to achieve their collection goal. 12, 13 The volume of blood processed each day was also based on our minimum predictive formula, 12 and ranged from 7 L to 30 L. The procedures were considered LVL when 30 L of whole blood and >4 3 the total blood volume (TBV) was processed (n 5 127; Optia® CMNC, n 5 59; COBE® Spectra, n 5 68). The remaining procedures were not considered LVL (non-LVL: 7-28 L whole blood and <4 3 TBV processed) (n 5 62; Optia® CMNC, n 5 34; COBE® Spectra, n 5 28). The collection goal at our institution is at least 20 /L and no history of aspirin allergy were given 81 mg acetyl salicyclic acid (ASA) immediately prior to collection to minimize the incidence of clotting in the HPC products.
14 All patients had a high flow central venous line placed for collection by interventional radiology. Optia® CMNC inlet and collect flow rates were set at 142 mL/minute and 1.5 mL/minute respectively. COBE® Spectra collection parameters were inlet flow rate of 150 mL/minute and collection flow rate 1.5 mL/minute, with anticoagulant infused at 5 mL/minute and inlet: anti-coagulant ratio of 31:1. For both devices 1000 mL anticoagulant citrate dextrose (ACD) and 5000 units heparin for anticoagulation were used for anticoagulation and infusion of 2 g calcium chloride in 250 mL normal saline (0.9% sodium chloride) ran at 85 mL/h. During collection 10 mL of ACD was added to the component at processed volumes of 10 L, 20 L, and 30 L for both devices. Optia® CMNC (CMNC program, software version 11.2) and COBE® Spectra (MNC program, software version 4.7) were used. The collection line was routinely checked and adjustments were made on the COBE® Spectra using the plasma pump; the target hematocrit was set at 2%-3%. Similar adjustments were made using the colorgram if needed on the Optia® CMNC system; otherwise a default setting of 50 was used.
| Data collection and analysis
The following data were recorded: age, sex, weight, height, diagnosis, mobilization regimen, preapheresis counts (WBC, platelet and CD341 counts), procedure run time, whole blood and total blood volume processed, postprocedure platelet count, HPC-A product parameters (volume, hematocrit, CD341 yield, viability), and evidence of adverse events was sought. Daily CD34 values prior to collection (precounts) were obtained by flow cytometry using a BD Procount TM kit (BD Biosciences, San Jose, California) on a FACSCalibur TM (BD Biosciences). Collection efficiency 2 (CE2) was determined as follows: total CD341 collected/WB Volume 3 pre-CD341. We calculated percent platelet loss as well as platelet loss per total blood volume processed. Hematology testing was performed on the Sysmex® XP-300 Automated Hematology Analyzer (utilizing the impedance method). 
Chemotherapy 1 G-CSF 1 plerixafor 67 CD341 cells in HPC-A products were quantified by flow cytometry on a FACSCalibur TM using the ISHAGE method. 15 Viability was assessed by flow cytometry on fresh cells prior to cryopreservation (prefreeze) using the 7-AAD uptake in CD341 cells. 16 Statistical analysis was performed using Excel (Microsoft Corporation®, Redmond, WA). Descriptive data is expressed as mean, median, range, and standard deviation. Comparison between the groups was performed by using Student's t test, and P < .05 was considered statistically significant.
| R ESULT S
| Collection results
No statistically significant differences were noted in the preapheresis WBC count between the two devices ( Table 3) . While the mean CD341 cells/mL (precounts) were higher in patients collecting on the Optia® CMNC than on the COBE® Spectra (149 versus 136.7 CD341 cells/mL), the results were not statistically significant. The procedure run time was also noted to be similar for both devices (mean values: Optia® CMNC 165.5 and COBE® Spectra 171 minutes), although the Optia® CMNC was slower than COBE® Spectra (142 mL/minute versus 150 mL/minute).
The number of CD341 cells collected was similar for both devices: Optia® CMNC (mean12.8; range 0.1-52.4 3 10 6 cells/kg) and COBE® Spectra (mean 11.2; range 0.2-76.5 3 10 6 cells/kg). No significant difference was seen in CE2 between the two devices (mean CE2: Optia® CMNC 42% and COBE® Spectra 41.6%). We further evaluated whether CE2 was affected by the volume of whole blood (WB) processed. As noted in Table 3 and Figure 1 , the mean CE2 was higher when <30 L whole blood was processed (Optia® CMNC 5 52.9%, standard deviation (SD) 18.6% and COBE® Spectra 5 48.9%, SD 16.7%) in comparison to 30 L (Optia® CMNC5 36.6%, SD 12.7% and COBE® Spectra5 38.9%, SD 13.9%). Optia® CMNC CE2 was higher when <30 L WB was processed and lower when 30 L WB was processed, but the results were not statistically significant in either case. We also evaluated whether the CD34 1 CE2 was affected by the preapheresis WBC count. While the COBE® Spectra CE2 showed no correlation with the preapheresis WBC count, we noted a peak in the Optia® CMNC CE2 when the preapheresis WBC count ranged between 25 and 30 3 10 9 /L (Figure 2 ). A linear correlation was noted between CD34 precount and CD341 cells collected for both systems ( Figure 3A) . A strong linear correlation was also noted between CD341 precounts and CD341 yields per liter of whole blood processed for both systems ( Figure 3B ). The same correlation was previously reported when we validated our minimum predicted collection formula on the COBE® Spectra system, 12 thus suggesting that our minimum predictive formula applies with the same accuracy on the new Optia® CMNC apheresis system. We next looked at the throughput (TP) of both devices. TP is expressed in CD341 cells collected per minute per CD341 cell/mL (precount). Unlike CE2, TP is not affected by the WB volume processed and is a better measure of the collection efficiency. As shown in Table 3 , the TP of the two devices is similar, again suggesting that similar results can be obtained from both devices.
| Platelet loss
Since most patients lose a significant number of platelets during HPC-A collection, we compared the preprocedure and postprocedure platelet counts to determine % platelet loss for the two devices. As noted in Table 3 , both devices showed similar platelet loss % (Optia® CMNC, mean 44%; and COBE® Spectra, mean 44.9). Since platelet loss depends on the total blood volume processed, with greater platelet loss noted when greater total blood volume is processed, we adjusted the % platelet loss for the total blood volume processed. The platelet loss % based on the total blood volume was also noted to be slightly less for Optia® CMNC (mean 9.3%, SD 3.5%) compared to COBE® Spectra (mean 10.5%, SD 3.8%), however the results did not achieve statistical significance. Thus, platelet loss based on whole blood volume processed using Optia® CMNC was 48.3% for 30 L whole blood processed and 31% for <30 L, compared to COBE® Spectra where 51.7% were lost for 30 L whole blood processed and 32.7% for <30 L.
| Product characteristics
No statistically significant differences were noted in the volume of the HPC-A products collected on the two devices. HPC-A products collected on Optia® CMNC had a lower %HCT (mean 3.7%, SD 1.9) than COBE® Spectra (mean 4.3%, SD 2.2), and the results were statistically significant (P 5 .029) ( Table 3) . We also compared the product RBC contamination, expressed as HPC product %HCT 3 product volume. Again we noted a statistically significant difference between the two devices; Optia® CMNC yielding a cleaner product than the COBE® Spectra (mean RBC contamination, 8.87 vs.11.79 mL of RBC; P 5 .005).
No correlation was noted between CD34 1 CE2% and product HCT%. No differences were noted in the product viability. No statistically significant differences were noted in the volume of the HPC-A products collected on the two devices.
| Adverse events
No adverse events were noted during collection, including anything related to high in-flow rates, citrate infusion, central line placement or ASA.
| DI SCU SSIO N
In this retrospective comparison study, we found that the performance of the new Optia® CMNC collection system is very similar to the COBE® Spectra collection system for both non-LVL and LVL collections from autologous donors.
F IGUR E 1
Comparison between the CE2% with the total blood volume processed. *denotes nonlarge volume leukapheresis (non-LVL) when <30 L whole blood or <4 3 TBV was processed. **denotes large volume leukapheresis (LVL) when 30L of whole blood and >4 3 total blood volume (TBV) was processed [Color figure can be viewed at wileyonlinelibrary.com]
To date, only a few studies have compared the performance characteristics of the two apheresis systems: Spectra Optia vs.Cobe Spectra 8 and MNC vs.CMNC Spectra Optia, 9 and no comparison studies have been reported from within the United States utilizing LVL. Our autologous donors who collected on the Optia® CMNC system had a median preapheresis WBC count 29.9 3 10 9 /L, and median preapheresis CD34 count 69/mL. These results are similar to that observed by Lamb et al. (preapheresis WBC 32 3 10 9 /L and CD34 63.5/mL), 17 Sanderson et al. /L and 69/mL). 9 The median number of CD341 cells/kg collected was higher in our study (8. We utilized the CE2 to determine the CE of the two apheresis systems in our study. Although CE2 does not accurately measure the true CE, it is a reasonable parameter for comparing two systems at a given center. 5 Our results showed no significant difference between the CE2 of the two devices (42% for Optia® CMNC versus 41.6% for COBE® Spectra). In a study of 23 healthy donors, Cancelas et al. noted a CE2 of 62.4% for Optia® CMNC and 48.4% for COBE® Spectra (P < 0.001). 19 However, other studies in autologous collectors with hematologoic malignancies have noted a wide range of CE2 (44%-56%) utilizing the two-step Spectra Optia® system. 5, 18, 20, 21 Lisenko et al., 9 in their study utilizing the Optia® CMNC system noted a CE2 of 50% in patients with multiple myeloma. A prior study by Douglas et al. showed that CE2 can vary between different centers, and is affected by a variety of factors such as the device settings, software version used and the exact apheresis hardware used. 22 Our results show a slightly lower CE2 (36.6%) when we processed 30 L WB (or 4 3 TBV). We saw a higher CE2 (50.6%) when <30 L WB (or <4 3 TBV) was processed, which is comparable to that seen in the previous studies. As noted by Ford et al. 23 and shown here, CE2 is not an No correlation was noted between preapheresis WBC count and CD34 1 CE2% for COBE® Spectra accurate measurement of the collection efficiency and can underestimate the actual CE, since it assumes that the pre-CD341 count remains constant throughout the procedure. Thus, when more blood is processed, a corresponding lower CE2 is noted.
As in previous studies, 17, 18 we noted a decrease in CD341 CE2 when the preapheresis WBC count was > 30 3 10 9 /L. Additionally, unlike prior studies, we noted that CD341 CE2 peaked when the preapheresis WBC count was 25-30 3 10 9 /L while using the Optia CMNC system. Like Lisenko et al., 9 we noted a linear correlation between the preapheresis CD34 cell counts and CD341 cells/kg collected, and no correlation between the preapheresis CD341 cell count and CD341 CE2. Additionally, we also noted a strong linear correlation between the CD341 cell precount and CD341 cells/kg collected per liter of whole blood volume processed. This strong linear correlation allows for predicting the total volume of whole blood required to be processed to achieve the collection goal. While it is impossible to predict the exact number of CD341 cells/kg in a collection, a given center may use the % collection efficiency for their devices to determine the minimum expected CD341 yield for a given volume of blood processed. At our center we used a minimum predictive formula utilizing a collection efficiency of 30% (peripheral blood CD341 cells/mL 3 0.3 3 volume of blood processed/body weight in kw). 12 This formula was established on the COBE® Spectra apheresis system, and is unaffected by the diagnosis, mobilization regimen, whether the patient is a good or bad mobilizer, and whether it is the first, second or later day of collection. While the formula predicts the minimum number of CD341 cells that are expected to be collected, it can be advantageous if more than the predicted number of cells are collected. We have noted that the more the patient overcollects the minimum prediction, the more likely the next day is to be a better collection than the first day (personal observation, Cottler-Fox, data not shown), which is helpful for planning purposes if a decision needs to be made about continuing collection, increasing G-CSF or adding plerixafor. Utilizing a minimum predictive formula and developing an institutional algorithm allows for reaching the collection goal in an efficient and economical manner, as collections for good mobilizers can be shorter than for poor mobilizers with decreased platelet loss resulting from the shorter collections and the need for plerixafor to salvage a failing collection can be anticipated. It is believed that the separate collection chamber in the Spectra Optia® MNC system reduces platelet attrition. In non-LVL studies, Brauninger et al. 24 and Cherqaoui et al. 25 reported a statistically significant decrease in platelet loss with the Spectra Optia® MNC system compared with the COBE® Spectra, while Reinhardt et al. 5 found no statistically significant differences between the two devices. Lisenko et al. 9 noted decreased platelet loss with the Optia® CMNC system compared with the Spectra Optia® MNC, but the results did not reach statistical significance. Cancelas et al. 19 reported a statistically significant decrease in platelet loss with the Optia® CMNC system compared to the COBE® Spectra system. Our results our similar to those of Cancelas and Lisenko et al., 9, 19 although a slightly higher platelet loss was noted in our study (42.9%) than in those studies (26% and 38% respectively). In contrast to the study by Cancelas et al. 19 but similar to Lisenko et al., 9 our results did not achieve statistical significance. We observed a significant platelet loss with both apheresis systems with LVL, losing an average of 60% on the COBE® Spectra when 30 L WB were processed. Although the platelet loss was slightly less while using the Optia® CMNC system, the results did not reach statistical significance. The product collected with the Optia® CMNC had a lower HCT and less RBC contamination than that collected with the COBE® Spectra. While Sanderson et al. noted a similar HPC product HCT (median 2%-3%) in their study, they did not compare it with the COBE® Spectra. Cancelas et al., 19 did not see any statistically significant differences between the two devices. These results may be possible if the operators chose a lighter interface, but no correlation was noted between the the product HCT% and CD341 CE2%. Although RBC contamination is not a great issue with autologous transplantation, it may be an important consideration in ABO incompatible allogeneic transplantation and MNC collection for therapeutic vaccine or immunotherapy production or photopheresis.
| CON CLU SIO N
In conclusion, the new Optia® CMNC apheresis system was as efficient as the COBE® Spectra in both LVL and non-LVL settings. Our previously established minimum predictive formula for the COBE® Spectra also applies, with the same accuracy, to the new Optia® CMNC apheresis system. A somewhat decreased platelet loss was observed when larger volumes of whole blood were processed, although this did not reach statistical significance. In addition, the HPC-A products collected using the Optia® CMNC tend to have a lower HCT.
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